A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, pharmacokinetic (PK), pharmacodynamic (PD) activity, and
preliminary anti-tumor activity of AND019 in women with advanced or metastatic estrogen
receptor (ER)-positive (human epidermal growth factor receptor 2 [HER2]-negative) breast
cancer.